Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
- None.
- None.
The issuance of U.S. Patent No. 11,938,295 marks a significant milestone for Biora Therapeutics in securing its intellectual property rights around the BioJet™ platform. The ability to protect the specific parameters of liquid jet delivery technology is pivotal for maintaining a competitive edge in the biotech field. The patent not only reinforces Biora's proprietary position but also potentially extends the company's revenue stream through licensing deals or partnerships. The BioJet platform's versatility in delivering a wide range of liquid drugs directly to the GI tract, bypassing the need for injections, presents a disruptive innovation in drug delivery systems.
From an investment perspective, the robust patent portfolio comprising 73 patent families signals to shareholders and potential investors that Biora is serious about safeguarding its innovations. This could translate into investor confidence and possibly an uplift in stock value as the market often reacts positively to strong intellectual property portfolios in the biotech sector. However, the actual impact on the stock market would be contingent on the platform's progression through clinical trials, regulatory approval and market adoption.
The oral delivery of biotherapeutics represents a substantial market opportunity, given the preference for oral administration over injections among patients. Biora's BioJet™ platform could address this demand and the patent for liquid jet delivery technology enhances its marketability. If the platform proves to be as effective as subcutaneous injections in terms of systemic bioavailability and consistency, it may capture a significant share of the market currently dominated by injectables.
However, the long-term success of the BioJet platform will depend on factors such as efficacy, safety, cost-effectiveness and the ability to scale production. The potential to deliver large molecules orally is particularly intriguing, as it opens the door to a new class of treatments that were previously limited to injection. Biora's strategy to achieve liver-targeted delivery could also be a game-changer for hepatic diseases. The company's comprehensive patent position is likely to attract partnerships with larger pharmaceutical companies looking to expand their delivery options for existing and pipeline drugs.
Securing a patent such as U.S. Patent No. 11,938,295 is a complicated and strategic legal endeavor, especially in the highly competitive biotech industry. Biora Therapeutics' success in this regard demonstrates a well-executed intellectual property strategy. The legal protection afforded by this patent not only safeguards the company's technology but also provides leverage in negotiations with potential partners or in defense against competitive infringement.
It's important to note that while patents provide a significant competitive moat, they also come with the responsibility of defending them, which can be costly and time-consuming. Additionally, the global scope of Biora's patent portfolio, with filings in major jurisdictions, indicates a proactive approach to international market entry and protection, which is essential for a biotech company with aspirations for global reach. The legal strength of these patents will be a critical factor in the company's ability to monetize its platform and maintain market exclusivity.
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,938,295 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract.” The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal (GI) tract, including the stomach or small intestine.
“This latest patent further secures Biora’s broad and comprehensive ownership of liquid jet delivery to the GI tract. The BioJet platform’s liquid jet injection technology, with systemic bioavailability and consistency shown to be comparable to traditional subcutaneous injection, is outperforming our performance targets in preclinical testing,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “Our approach also allows for the delivery of multi-milligram doses of nearly any liquid drug, with minimal to no reformulation. The BioJet platform’s potential to deliver large molecules, including GLP-1 agonists, monoclonal antibodies, antisense oligonucleotides, and many others, and to achieve liver-targeted delivery through the hepatic portal, could transform oral delivery of therapeutics,” stated Mr. Mohanty.
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora’s larger corporate portfolio consisting of 73 patent families, including approximately 190 issued patents and 136 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico.
About the BioJet™ Systemic Oral Delivery Platform
Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver a drug directly into the small intestine for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.
About Biora Therapeutics
Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms: the clinical-stage NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the preclinical-stage BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, and the potential of the BioJet platform, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “forward,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
media@bioratherapeutics.com
